<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022098</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1143-201</org_study_id>
    <nct_id>NCT02022098</nct_id>
  </id_info>
  <brief_title>Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial</brief_title>
  <official_title>A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of multiple drugs in a single clinical trial or as a therapeutic strategy has become
      common, particularly in the treatment of cancer. Because traditional trials are designed to
      evaluate one agent at a time, the evaluation of therapies in combination requires specialized
      trial designs. In place of the traditional separate phase I and II trials, this trial uses a
      single phase I/II clinical trial to evaluate simultaneously the safety and efficacy of
      combination dose levels, and select the optimal combination dose.

      Therefore, this is a two part trial of Debio 1143 combined with concurrent cisplatin and
      radiotherapy (CRT) in participants with previously untreated stage III, IVa or IVb head and
      neck cancer. The trial begins with an initial period of dose escalation (Phase I) to
      investigate the maximum tolerated dose (MTD) of Debio 1143 that can safely be given in
      combination with CRT.

      Using the MTD determined in the Phase I portion, the randomized phase II trial in 94
      participants compares Debio 1143 to placebo, both with concomitant CRT. The aim is to
      evaluate the efficacy and safety of Debio 1143.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II: Percentage of participants achieving Locoregional Control (LRC) at 18 months from the end of chemo-radiation therapy (CRT)</measure>
    <time_frame>within 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Complete Response Rate (by RECIST version 1.1) at six months after completion of chemo-radiation therapy (CRT) therapy</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Best Overall response rate, Disease Control rate and Response Rate after 10 weeks from the end of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Best Overall response rate, Disease Control rate and Response Rate after 6 months from the end of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Locoregional control rate at 6 months and one year after completion of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression free survival rate at one year, 18 months and at 2 years as of initiation of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Distant relapse rate at six months, one year and 18 months after completion of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Disease specific survival rate one year and at 2 years as of initiation of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall survival rate at one year and at 2 years as of initiation of CRT</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with clinically significant change in vital signs during participation in the trial</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with Serious Adverse Events</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with Adverse Events (AEs)</measure>
    <time_frame>within 5 years</time_frame>
    <description>Categories will be based on severity graded according to NCI-CTCAE version 4 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with Laboratory Abnormalities</measure>
    <time_frame>within 5 years</time_frame>
    <description>Categories will be based on severity graded according to NCI-CTCAE version 4 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with Late Toxicity as of initiation of CRT</measure>
    <time_frame>within 5 years</time_frame>
    <description>Categories: at 1 year, at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of participants with treatment changes due to AEs</measure>
    <time_frame>within 5 years</time_frame>
    <description>Categories: Treatment discontinuation, Treatment modification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.</description>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Concomitant Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.</description>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Concomitant Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Debio 1143</intervention_name>
    <description>Debio 1143 solution</description>
    <arm_group_label>Debio 1143</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Is willing and able to comply with study procedures and restrictions related to food,
             drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  Has history or current use of over-the-counter medications, dietary supplements, or
             drugs (including nicotine and alcohol) outside protocol-specified parameters

          -  Has signs, symptoms or history of any condition that, per protocol or in the opinion
             of the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud - HÔPITAL DU SCORFF</name>
      <address>
        <city>Lorient</city>
        <state>Bp 2233</state>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sud Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers Cedex 02</city>
        <zip>CS 10059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>CAEN Cedex 09</city>
        <zip>CS30001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand Cedex 01</city>
        <zip>BP 392</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>BP 217</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon cedex 9</city>
        <zip>F- 85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Guillaume le Conquérant</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <zip>25200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM - Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest (ICO) René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>BP 217</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth (ICLN)</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>BP 60008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Institut de Cancérologie de Lorraine (ICL) Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>CS 30519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern, Universitätsklinik für Radio-Onkologie, Freiburgstrasse 4</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

